The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics.
Get PDF Brochure for Research Insights @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724
The digital therapeutics market is a highly diversified and competitive market, with several emerging players. The prominent players in this market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics
Noom (US)
Noom (US) is one of the leading providers of the digital therapeutics market. The company provides best-in-class solutions for weight management, hypertension prevention, hypertension management, diabetes prevention, diabetes management, and comorbidities of hypertension and diabetes. The company adopts organic as well as inorganic strategies to strengthen its position in the digital therapeutics market.
Omada (US)
Omada is one of the leading players in the digital therapeutics market. The company is engaged in designing and developing innovative digital therapeutic programs for preventable chronic diseases, including type 2 diabetes and heart disease. The company sells its products to major organizations, integrated delivery networks, and health plans. The company has attracted significant investments to enhance its solutions, particularly its digital prediabetes program ‘Prevent.
Livongo Health (US)
Livongo Health (US) is one of the prominent players in the digital therapeutics market. The company focuses mainly on digital solutions for the management of chronic diseases. The company’s diabetes management solution has helped in reducing medical spending. Iron Mountain Incorporated (US) and Dean Foods (US), among others, have shared the positive impacts of Livongo’s diabetes management program.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724
Recent Developments:
- Welldoc(US) partnered with Dexacom (US). This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.
- Pear Therapeutics (US) partnered with Sprectrum Health Systems (US). Tufts Health Plan and Spectrum Health Systems announced a collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation
- Crossroads Treatment Centers (US) collaborated with Pear Therapeutics (US) to implement the company’s digital platform reSET-O to help patients with opioid abuse and addiction.
Frequently Asked Questions (FAQ):
- Which application segment will dominate the Digital therapeutics market in the future?
- Emerging countries have immense opportunities for the growth and adoption Digital therapeutics market; will this scenario continue in the next five years?
- Who are the leading players in the Digital therapeutics market?
- What are the major Application in the Digital therapeutics market?
Speak to Our Analyst and gain crucial industry insights that will help your business grow @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724
